The gastroesophageal cancer market (including gastric, gastroesophageal junction, and esophageal cancer) is witnessing a substantial change, largely fueled by the entry of immune checkpoint…
The unipolar depression therapy market is crowded and highly genericized. The prominent use of drugs such as selective serotonin reuptake inhibitors (SSRIs) as early-line treatments contributes to…
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic…
Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon…
Prostate Cancer
The wet age-related macular degeneration (AMD) therapy market has long been dominated by three VEGF inhibitors: Roche / Genentech / Chugai’s Avastin, Roche / Genentech / Novartis’s Lucentis,…
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment durations. The availability of premium-priced branded agents prescribed…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging…
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant…
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Although the tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first…
Retinal Vein Occlusion
Methicillin-Resistant Staphylococcus Aureus Infections
Chronic Fatigue Syndrome
Pre-exposure prophylaxis (PrEP) is a key prevention strategy for ending the human immunodeficiency virus (HIV) epidemic. The FDA’s approval of Gilead’s Truvada in 2012 and Descovy in 2019…